IN188419B - - Google Patents

Info

Publication number
IN188419B
IN188419B IN3276DE1998A IN188419B IN 188419 B IN188419 B IN 188419B IN 3276DE1998 A IN3276DE1998 A IN 3276DE1998A IN 188419 B IN188419 B IN 188419B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Ulrich Niewohner
Mazen Es-Sayed
Helmut Haning
Thomas Schenke
Karl-Heinz Schlemmer
Jorg Keldenich
Erwin Bischoff
Elisabeth Perzborn
Klaus Dembowsky
Peter Serno
Marc Nowakowski
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN188419(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19750085A external-priority patent/DE19750085A1/de
Priority claimed from DE1998112462 external-priority patent/DE19812462A1/de
Priority claimed from DE1998140289 external-priority patent/DE19840289A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IN188419B publication Critical patent/IN188419B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN3276DE1998 1997-11-12 1998-11-05 IN188419B (index.php)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19750085A DE19750085A1 (de) 1997-11-12 1997-11-12 2-Phenyl-substituierte Imidazotriazinone
DE1998112462 DE19812462A1 (de) 1998-03-23 1998-03-23 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
DE1998140289 DE19840289A1 (de) 1998-09-04 1998-09-04 2-Phenyl-substituierte Imidazotriazinone

Publications (1)

Publication Number Publication Date
IN188419B true IN188419B (index.php) 2002-09-21

Family

ID=27217917

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3276DE1998 IN188419B (index.php) 1997-11-12 1998-11-05

Country Status (43)

Country Link
US (9) US6362178B1 (index.php)
EP (3) EP1174431B1 (index.php)
JP (2) JP3356428B2 (index.php)
KR (2) KR100548120B1 (index.php)
CN (2) CN1123573C (index.php)
AR (2) AR013759A1 (index.php)
AT (1) ATE213246T1 (index.php)
AU (1) AU738675B2 (index.php)
BG (1) BG65257B1 (index.php)
BR (2) BR9812785A (index.php)
CA (2) CA2309332C (index.php)
CH (1) CH693954A5 (index.php)
CO (1) CO4980861A1 (index.php)
CU (1) CU23063A3 (index.php)
CY (1) CY1112949T1 (index.php)
CZ (1) CZ301911B6 (index.php)
DE (3) DE59803108D1 (index.php)
DK (3) DK1174431T3 (index.php)
EE (1) EE04781B1 (index.php)
ES (3) ES2194567B1 (index.php)
FI (1) FI113772B (index.php)
GB (1) GB2346877B (index.php)
HN (1) HN1998000175A (index.php)
HR (2) HRP20000292B1 (index.php)
HU (3) HU228196B1 (index.php)
ID (1) ID25871A (index.php)
IL (3) IL135462A0 (index.php)
IN (1) IN188419B (index.php)
LU (1) LU90561B1 (index.php)
MY (1) MY138535A (index.php)
NO (2) NO314940B1 (index.php)
NZ (1) NZ504436A (index.php)
PE (1) PE131799A1 (index.php)
PL (2) PL194801B1 (index.php)
PT (2) PT1174431E (index.php)
SE (1) SE522809C2 (index.php)
SI (2) SI1049695T1 (index.php)
SK (1) SK287161B6 (index.php)
TR (1) TR200001338T2 (index.php)
TW (2) TWI229081B (index.php)
UA (1) UA46166C2 (index.php)
UY (2) UY25246A1 (index.php)
WO (1) WO1999024433A1 (index.php)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
IL135462A0 (en) * 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
IL139456A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
EP1244673A2 (de) 1999-12-24 2002-10-02 Bayer Aktiengesellschaft Imidazo[1,3,5]triazinone und ihre verwendung
DE50008549D1 (de) 1999-12-24 2004-12-09 Bayer Healthcare Ag Triazolotriazinone und ihre verwendung
AU2365001A (en) 1999-12-24 2001-07-09 Bayer Aktiengesellschaft Isoxazolo pyrimidinones and the use thereof
DE10010067A1 (de) 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
WO2001078711A2 (en) 2000-04-19 2001-10-25 Lilly Icos, Llc. Pde-v inhibitors for treatment of parkinson's disease
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
JP5069392B2 (ja) * 2000-09-29 2012-11-07 グラクソ グループ リミテッド 炎症性疾患の処置に有用な化合物
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
DE10063106A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von 2-(2-Ethoxyphenyl)-substituierten Imidazotriazinonen
DE10063108A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
JP2004527476A (ja) * 2001-02-02 2004-09-09 ファイザー・インク 真性糖尿病の処置
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
PL363679A1 (en) * 2001-05-09 2004-11-29 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
GB0113344D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE60226615D1 (index.php) 2001-08-28 2008-06-26 Schering Corp
US6943171B2 (en) 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
ATE375347T1 (de) * 2001-12-13 2007-10-15 Asubio Pharma Co Ltd Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0209988D0 (en) * 2002-05-01 2002-06-12 Bayer Ag Novel Heterocycles
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003265239A1 (en) 2002-05-22 2003-12-19 Virginia Commonwealth University Protective effects of pde-5 inhibitors
CN1655820A (zh) * 2002-05-23 2005-08-17 辉瑞大药厂 Pde5抑制剂与ace抑制剂的药物组合
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
EP1572173B1 (en) 2002-12-13 2010-04-28 Warner-Lambert Company LLC Alpha-2-delta ligand to treat lower urinary tract symptoms
ATE432936T1 (de) 2003-04-01 2009-06-15 Smithkline Beecham Corp Imidazotriazin verbindungen zur behandlung von krebserkrankungen
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1625334B9 (en) 2003-05-21 2012-07-25 Alexza Pharmaceuticals, Inc. Percussively ignited self-contained heating unit
JP2006528229A (ja) 2003-05-22 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト Ｐｄｅ４阻害剤及びｐｄｅ５阻害剤を含有する組成物
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
EP1691788A2 (en) * 2003-11-21 2006-08-23 Schering Corporation Phosphodiesterase v inhibitor formulations
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2007518788A (ja) 2004-01-22 2007-07-12 ファイザー・インク バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
WO2005097799A1 (en) * 2004-04-07 2005-10-20 Pfizer Limited Pyrazolo`4,3-d! pyrimidines
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
JP2008501617A (ja) * 2004-06-11 2008-01-24 アスビオファーマ株式会社 Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
WO2006022714A1 (en) 2004-08-12 2006-03-02 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
ZA200707506B (en) * 2005-02-18 2009-08-26 Surface Logix Inc Method of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
US20080176844A1 (en) * 2005-02-18 2008-07-24 Stewart Campbell Pharmacokinetically Improved Compounds
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
PT2366393E (pt) 2005-04-19 2013-10-04 Takeda Gmbh Roflumilaste para o tratamento da hipertensão pulmonar
MX2007013215A (es) 2005-05-12 2007-12-12 Pfizer Formas cristalinas anhidras de la n-[1-(2-etoxietil)-5-(n-etil-n- metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo[4,3-d] pirimidina -3-carbonil] metanosulfonamida.
WO2006127368A2 (en) * 2005-05-20 2006-11-30 Lexicon Genetics Incorporated Methods for synthesizing imidazotriazinones
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
WO2007017752A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009509984A (ja) 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200736195A (en) * 2006-02-17 2007-10-01 Wyeth Corp Methods for preparing sulfonamide substituted alcohols and intermediates thereof
WO2007098030A1 (en) * 2006-02-17 2007-08-30 Wyeth Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7977478B2 (en) * 2006-03-13 2011-07-12 Dr. Reddy's Laboratories Limited Polymorphic forms of vardenafil
BRPI0708804B8 (pt) * 2006-03-17 2021-05-25 Cardioxyl Pharmaceuticals Inc compostos derivados de n-hidroxilsulfonamida como doadores de nitroxil, composição farmacêutica e kit
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2655061A1 (en) 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
BRPI0716571A2 (pt) * 2006-08-24 2013-11-05 Surface Logix Inc Compostos farmacocineticamente otimizados
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SI2101777T1 (sl) 2006-12-12 2015-08-31 Gilead Sciences, Inc. Sestavek za zdravljenje pljučne hipertenzije
WO2008100886A1 (en) * 2007-02-12 2008-08-21 Auspex Pharmaceuticals, Inc. Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction
EP2120570B1 (en) * 2007-02-12 2012-05-16 DMI Biosciences, Inc. Treatment of comorbid premature ejaculation and erectile dysfunction
KR20130122023A (ko) * 2007-02-12 2013-11-06 디엠아이 바이오사이언시스 인코포레이티드 트라마돌의 부작용을 감소시키는 방법
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
CA2689638A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
CN101965348B (zh) * 2007-09-06 2013-11-13 上海特化医药科技有限公司 伐地那非的制备方法及其中间体
EP2228370B1 (en) 2007-12-28 2012-05-23 Topharman Shanghai Co., Ltd. N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)benzenesulfonyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
WO2011016016A1 (en) 2009-08-07 2011-02-10 Ranbaxy Laboratories Limited Processes for the preparation of vardenafil
NZ715101A (en) * 2009-11-27 2017-07-28 Adverio Pharma Gmbh Method for producing methyl-{ 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
JP5806231B2 (ja) 2009-12-21 2015-11-10 アセフ エス．アー． 勃起障害の治療における血管拡張剤としてのクベビン、ジベンジルブチルロラクトリンリグナン、その半合成誘導体および合成誘導体、ならびに他のリグナンおよびネオリグナン
PL390079A1 (pl) * 2009-12-30 2011-07-04 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
WO2011126250A2 (ko) 2010-04-05 2011-10-13 에스케이케미칼 주식회사 Pde5 억제제를 함유하는 피부 주름 개선용 조성물
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN102382129B (zh) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 螺环取代的磷酸二酯酶抑制剂
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
US20120157458A1 (en) 2010-09-20 2012-06-21 Amy Ripka Imidazotriazinone compounds
CN106074548A (zh) 2010-09-23 2016-11-09 艾伯维巴哈马有限公司 氮杂金刚烷衍生物的一水合物
JP5806320B2 (ja) 2010-10-15 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 肺高血圧症を処置するための組成物および方法
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
HK1211023A1 (zh) 2011-10-10 2016-05-13 H. Lundbeck A/S 具有咪唑并吡嗪骨架pde9i
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CZ2011767A3 (cs) 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
CN107082783B (zh) 2012-01-26 2019-03-22 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
WO2013129889A2 (ko) 2012-02-28 2013-09-06 주식회사 서울제약 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
CZ307091B6 (cs) 2012-09-14 2018-01-10 Zentiva, K.S. Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
EP3981409A1 (en) 2012-12-04 2022-04-13 Aribio Inc. Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
AP2015008670A0 (en) 2013-02-21 2015-08-31 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
CN104109164B (zh) * 2013-04-18 2016-05-25 广州朗圣药业有限公司 一种适合工业化的高纯度盐酸伐地那非三水合物的制备方法
ES2776353T3 (es) 2013-07-17 2020-07-30 Univ Columbia Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL223869B1 (pl) 2013-12-16 2016-11-30 Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna Sposób otrzymywania wardenafilu i jego soli
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
DK3377495T3 (da) 2015-11-16 2022-05-09 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinon-derivativer som phosphodiesterasehæmmere og anvendelser deraf
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
EP4696376A2 (en) 2017-05-22 2026-02-18 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CN107445964A (zh) * 2017-07-29 2017-12-08 合肥创新医药技术有限公司 一种盐酸伐地那非杂质的合成方法
BR112020012239A2 (pt) 2017-12-20 2020-11-24 Klaria Pharma Holding Ab método para preparar um filme mucoadesivo, e, filme mucoadesivo
WO2019152873A1 (en) 2018-02-02 2019-08-08 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
AU2019275075B2 (en) 2018-05-25 2024-11-28 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7H-imid azo [1,5- a] pyrazin-8-one
EP3807897A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
CN112997258A (zh) 2018-06-14 2021-06-18 阿斯利康(英国)有限公司 用cGMP特异性磷酸二酯酶5抑制剂药物组合物治疗勃起功能障碍的方法
CN119679736A (zh) 2018-08-31 2025-03-25 卡都瑞恩医药公司 用于治疗镰状细胞病的pde9抑制剂
MX2021005892A (es) 2018-11-28 2021-06-23 Topadur Pharma Ag Novedosos activadores de guanilato ciclasa soluble e inhibidores de fosfodiesterasa con modo de accion dual y usos de estos.
ES3040728T3 (en) 2019-03-13 2025-11-04 Otsuka Pharma Co Ltd Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CA3201054A1 (en) * 2020-12-11 2022-06-16 Yoon-Suk Lee Novel compounds as androgen receptor and phosphodiesterase dual inhibitor
EP4293023A4 (en) * 2021-04-21 2024-12-18 Changchun Genescience Pharmaceutical Co., Ltd. Imidazole-containing condensed ring derivative, preparation method therefor, and application thereof in medicine
CN114085225A (zh) * 2021-06-04 2022-02-25 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
WO2023052407A1 (en) 2021-09-29 2023-04-06 Topadur Pharma Ag Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
AU2023227111A1 (en) 2022-03-02 2024-07-25 Topadur Pharma Ag Topical compositions and uses therof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
EP4574826A4 (en) * 2022-10-19 2025-12-10 Changchun Genescience Pharmaceutical Co Ltd CRYSTALLINE FORM OF AN NK3R ANTAGONIST, ITS PREPARATION PROCESS AND ITS USE
AU2024220563A1 (en) 2023-02-16 2025-08-14 University Of Rochester Improving glymphatic-lymphatic efflux

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26565A (en) * 1859-12-27 Improved register for railroad-cars
DE812845C (de) 1944-12-07 1951-09-06 Georges Lissac Brille
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (index.php) 1963-01-16
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4287673A (en) * 1980-01-11 1981-09-08 Sunbeam Corporation Hair dryer diffuser
EP0054132B1 (de) 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
DE68908786T2 (de) 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
EP0524180B1 (en) * 1990-04-11 1995-04-26 The Upjohn Company Taste masking of ibuprofen by fluid bed coating
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) * 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
CA2148260A1 (en) 1993-09-10 1995-03-16 Yasutaka Takase Quinazoline cpompounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5374053A (en) * 1994-01-21 1994-12-20 Heidelberger Druckmaschinen Ag Device for changing the transport position of products
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
EP1244673A2 (de) * 1999-12-24 2002-10-02 Bayer Aktiengesellschaft Imidazo[1,3,5]triazinone und ihre verwendung
PL363679A1 (en) 2001-05-09 2004-11-29 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel

Also Published As

Publication number Publication date
IL135462A0 (en) 2001-05-20
ES2194567B1 (es) 2005-03-01
DK1174431T3 (da) 2012-08-20
DK1049695T3 (da) 2002-05-13
DE59803108D1 (de) 2002-03-21
JP2001522851A (ja) 2001-11-20
US7122540B2 (en) 2006-10-17
HUP0100394A2 (hu) 2001-09-28
PT1174431E (pt) 2012-07-24
CA2395558C (en) 2007-07-17
BG104406A (en) 2001-08-31
AR013759A1 (es) 2001-01-10
DK176852B1 (en) 2009-12-14
US6566360B1 (en) 2003-05-20
TW513431B (en) 2002-12-11
GB2346877B (en) 2001-12-05
CN1278822A (zh) 2001-01-03
AU1558799A (en) 1999-05-31
PL194801B1 (pl) 2007-07-31
KR20040014591A (ko) 2004-02-14
NZ504436A (en) 2001-08-31
EE04781B1 (et) 2007-02-15
EP1049695B1 (de) 2002-02-13
HRP20000292B1 (hr) 2008-09-30
ES2386420T3 (es) 2012-08-20
BR9812785A (pt) 2000-10-10
CA2309332C (en) 2002-12-03
US7314871B2 (en) 2008-01-01
EP1174431A3 (de) 2002-01-30
GB0010974D0 (en) 2000-06-28
HK1067124A1 (zh) 2005-04-01
HN1998000175A (es) 1999-01-08
US20050070541A1 (en) 2005-03-31
HUP0100394A3 (en) 2002-05-28
SE0001745D0 (sv) 2000-05-11
US20130059844A1 (en) 2013-03-07
US20110009367A1 (en) 2011-01-13
HRP20000292A2 (en) 2001-04-30
HRP20020585B1 (hr) 2013-02-28
IL163475A (en) 2015-11-30
SI1174431T1 (sl) 2012-09-28
ATE213246T1 (de) 2002-02-15
CO4980861A1 (es) 2000-11-27
UY25671A1 (es) 2000-03-31
CH693954A5 (de) 2004-05-14
MY138535A (en) 2009-06-30
SK7092000A3 (en) 2001-03-12
BG65257B1 (bg) 2007-10-31
KR100548120B1 (ko) 2006-02-02
US20100016323A1 (en) 2010-01-21
NO314940B1 (no) 2003-06-16
KR20010031944A (ko) 2001-04-16
KR100430355B1 (ko) 2004-05-04
AU738675B2 (en) 2001-09-20
HK1031730A1 (en) 2001-06-22
PT1049695E (pt) 2002-07-31
US7696206B2 (en) 2010-04-13
CZ301911B6 (cs) 2010-07-28
ID25871A (id) 2000-11-09
CA2395558A1 (en) 1999-05-20
PL201336B1 (pl) 2009-03-31
US20040067945A1 (en) 2004-04-08
SE0001745L (sv) 2000-05-11
BR9816155B1 (pt) 2010-07-27
SI1049695T1 (en) 2002-06-30
EP2295436A1 (de) 2011-03-16
DE19881732C1 (de) 2002-01-31
HU227841B1 (en) 2012-05-02
EP1049695A1 (de) 2000-11-08
NO20002444L (no) 2000-05-11
CU23063A3 (es) 2005-07-19
EE200000291A (et) 2001-06-15
PE131799A1 (es) 1999-12-30
AR035972A2 (es) 2004-07-28
US20080113972A1 (en) 2008-05-15
SE522809C2 (sv) 2004-03-09
CN1508137A (zh) 2004-06-30
FI113772B (fi) 2004-06-15
JP4388729B2 (ja) 2009-12-24
EP1174431A2 (de) 2002-01-23
CN1123573C (zh) 2003-10-08
US6890922B2 (en) 2005-05-10
PL340400A1 (en) 2001-01-29
ES2194567A1 (es) 2003-11-16
NO20021714L (no) 2000-05-11
US7704999B2 (en) 2010-04-27
EP1174431B1 (de) 2012-05-30
ES2172945T3 (es) 2002-10-01
HRP20020585A2 (en) 2005-10-31
WO1999024433A1 (de) 1999-05-20
DE19881732D2 (de) 2000-08-24
NO20021714D0 (no) 2002-04-11
NO20002444D0 (no) 2000-05-11
DK200000766A (da) 2000-05-09
TWI229081B (en) 2005-03-11
US6362178B1 (en) 2002-03-26
UY25246A1 (es) 2001-08-27
SK287161B6 (sk) 2010-02-08
UA46166C2 (uk) 2002-05-15
HU230154B1 (hu) 2015-09-28
CA2309332A1 (en) 1999-05-20
CY1112949T1 (el) 2016-04-13
US20060189615A1 (en) 2006-08-24
TR200001338T2 (tr) 2000-08-21
HU228196B1 (en) 2013-01-28
LU90561B1 (de) 2000-12-01
FI20001086L (fi) 2000-05-09
CN100430396C (zh) 2008-11-05
IL135462A (en) 2006-04-10
CZ20001759A3 (cs) 2000-10-11
GB2346877A (en) 2000-08-23
JP2002348290A (ja) 2002-12-04
JP3356428B2 (ja) 2002-12-16

Similar Documents

Publication Publication Date Title
BE2018C032I2 (index.php)
IN188411B (index.php)
CH0944937H2 (index.php)
ITMI971064A0 (index.php)
IN188375B (index.php)
BE2013C047I2 (index.php)
IN185765B (index.php)
ITMI970507V0 (index.php)
IN192432B (index.php)
BR9700653A (index.php)
IN191986B (index.php)
BR9701757A (index.php)
ITMI971220A0 (index.php)
IN188732B (index.php)
ITVI970055A0 (index.php)
ECSMU970103U (index.php)
CN3058000S (index.php)
CN3057613S (index.php)
BY4238C1 (index.php)
CN3056418S (index.php)
CN3058138S (index.php)
CN3058088S (index.php)
CN3058057S (index.php)
CN3058025S (index.php)
CN3055123S (index.php)